NEONC TECHNOLOGIES HOLDINGS (NTHI) Stock Price, Forecast & Analysis
USA - NASDAQ:NTHI - US64051A1016 - Common Stock
NTHI Key Statistics, Chart & Performance
The current stock price of NTHI is 7.96 USD. In the past month the price decreased by -19.6%.
NTHI Latest News, Press Relases and Analysis
NTHI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.46 | 967.00B | ||
| JNJ | JOHNSON & JOHNSON | 19.23 | 480.66B | ||
| MRK | MERCK & CO. INC. | 10.54 | 231.94B | ||
| PFE | PFIZER INC | 7.84 | 142.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.14 | 95.28B | ||
| ZTS | ZOETIS INC | 18.74 | 52.65B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.58 | 12.43B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.31 | 10.64B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.36 | 7.92B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.26B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.10B |
Related stock screener links
About NTHI
Company Profile
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Company Info
NEONC TECHNOLOGIES HOLDINGS
23975 Park Sorrento, Suite 205
Calabasas CALIFORNIA US
Employees: 3
Phone: 13106637831
NEONC TECHNOLOGIES HOLDINGS / NTHI FAQ
Can you describe the business of NEONC TECHNOLOGIES HOLDINGS?
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
What is the stock price of NEONC TECHNOLOGIES HOLDINGS today?
The current stock price of NTHI is 7.96 USD. The price decreased by -12.33% in the last trading session.
What is the dividend status of NEONC TECHNOLOGIES HOLDINGS?
NTHI does not pay a dividend.
What is the ChartMill technical and fundamental rating of NTHI stock?
NTHI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists NTHI stock?
NTHI stock is listed on the Nasdaq exchange.
What is NEONC TECHNOLOGIES HOLDINGS worth?
NEONC TECHNOLOGIES HOLDINGS (NTHI) has a market capitalization of 152.51M USD. This makes NTHI a Micro Cap stock.
NTHI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NTHI.
NTHI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NTHI. NTHI may be in some trouble as it scores bad on both profitability and health.
NTHI Financial Highlights
Over the last trailing twelve months NTHI reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 20.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1420.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |